Company / Operating Income
Theravance Biopharma, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$3.6M
FY2025
5-year range
-$297.6M / -$3.6M
FY2021-FY2025
Trend
+92.3%
vs FY2024
Sector context
#57 of 204
Health Care
What the data says
At -$4M, Theravance Biopharma, Inc.'s operating income ranks #57 of 204 in the Health Care sector. Operating Income has increased for 3 consecutive years, from -$298M in FY2022 to -$4M in FY2025.
Based on SEC 10-K filings.
-$4M in FY2025.
Improved from -$56M to -$4M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#57 of 204 in Health CareTop 28% of 204This company -$3.6M Sector average $107.7M
▼
-103.3% below sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s operating income has grown for 3 consecutive years.
- In FY2025, operating income increased 92.3% year-over-year.
- Ranks #57 out of 204 companies in the Health Care sector.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.6M | +92.3% |
| FY2024 | -$46.9M | +16.2% |
| FY2023 | -$56.0M | +81.2% |
| FY2022 | -$297.6M | -15.5% |
| FY2021 | -$257.8M | +13.4% |
| FY2020 | -$297.6M | -14.4% |
| FY2019 | -$260.1M | -44.1% |
| FY2018 | -$180.5M | +30.6% |
| FY2017 | -$260.1M | -44.1% |
| FY2016 | -$180.5M | -15.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026